• 1
    [No authors listed] Polychemotherapy for early breast cancer: an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352: 930942.
  • 2
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? [see comment]. J Clin Oncol. 2004; 22: 17971806.
  • 3
    Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005; 23: 66396646.
  • 4
    Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21: 45244531.
  • 5
    Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21: 602606.
  • 6
    Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003; 41: 442446.
  • 7
    Silliman RA, Guadagnoli E, Weitberg AB, et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989; 44: M46M50.
  • 8
    Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006; 65: 13531360.
  • 9
    Hershman DL Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006; 99: 313321.
  • 10
    Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study [see comment]. J Clin Oncol. 2002; 20: 26432650.
  • 11
    Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 39994005.
  • 12
    Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97: 12111220.
  • 13
    Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001; 7: 213218.
  • 14
    Neugut AI, Matsar M, Wang X, McBride R, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006; 24: 23682375.
  • 15
    Dobie SA, Baldwin LM, Dominitz JA, et al. Completion of therapy by Medicare patients with stage III colon cancer [see comment]. J Natl Cancer Inst. 2006; 98: 610619.
  • 16
    Rulyak SJ, Mandelson MT, Brentnall TA, et al. Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer. Gastrointest Endosc. 2004; 59: 239247.
  • 17
    Rolnick S, Hensley Alford S, Kucera GP, et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr. 2005;(35): 96101.
  • 18
    Holliday HW, Hardcastle JD. Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet. 1979; 1: 309311.
  • 19
    Langenbach MR, Schmidt J, Neumann J, et al. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg. 2003; 27: 304308.
  • 20
    Caplan LS. Disparities in breast cancer screening: is it ethical? Public Health Rev. 1997; 25: 3141.
  • 21
    Caplan LS, Wells BL, Haynes S. Breast cancer screening among older racial/ethnic minorities and whites: barriers to early detection. J Gerontol. 1992; 47(spec no): 101110.
  • 22
    Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol. 1990; 8: 14661475.
  • 23
    Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11: 18791887.
  • 24
    Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998; 90: 18101816.
  • 25
    Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare- tumor registry database. Med Care. 1993; 31: 732748.
  • 26
    Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 12581267.
  • 27
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-55IV-61.
  • 28
    Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer [see comment]. N Engl J Med. 1999; 341: 11981205.
  • 29
    Charlson ME, Sax FL, MacKenzie CR, et al. Assessing illness severity: does clinical judgment work? J Chron Dis. 1986; 39: 439452.
  • 30
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 31
    Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002; 40: IV-26IV-35.
  • 32
    Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005; 23: 18191825.
  • 33
    Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005; 89: 771793.
  • 34
    Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J the Natl Cancer Inst. 2001; 93: 850857.
  • 35
    Colleoni M, Price K, Castiglione-Gertsch M, et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1998; 34: 16931700.
  • 36
    Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003; 21: 37923797.
  • 37
    Cold S, During M, Ewertz M, et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?. Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005; 93: 627632.
  • 38
    Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol. 2006; 24: 626634.
  • 39
    Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000; 35: 181200.
  • 40
    Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 15821587.